DPP-4 Inhibitors May Not Be Linked to Increased Heart Attack Risk

The Wall Street Journal reported that research presented at the European Society of Cardiology Congress and published in the New England Journal of Medicine suggests that the diabetes medications known as DPP-4 inhibitors may not be linked to an increased heart attack risk. One study involved Onglyza (saxagliptin) and the other involved Nesina (alogliptin).